Abstract
BACKGROUND: Uveal melanoma, a rare and aggressive intraocular malignancy, poses significant challenges due to its high metastatic potential. Tebentafusp, an innovative immunotherapy targeting melanoma-associated antigens, has shown promise in early clinical trials for metastatic uveal melanoma. METHODS: This systematic review adhered to PRISMA guidelines, analyzing four studies encompassing 475 patients until January 18, 2024. Meta-analysis techniques, utilizing RevMan software version 5.4, were employed to calculate hazard ratios (HR) or risk ratios (RR) with their respective 95% confidence intervals for each outcome. RESULTS: The 1-year overall survival rate, pooled from the included studies, was 68% with moderate heterogeneity (I2=56%, p=0.1). Cytokine release syndrome was observed in 83% of patients across three studies, with high heterogeneity (I2=79%, p<0.01). CONCLUSION: Our findings underscore modest responses and manageable adverse effects such as cytokine release syndrome and fatigue, highlighting the necessity for careful monitoring and proactive management in the clinical application of Tebentafusp for metastatic uveal melanoma.